Jafron Biomedical (300529.SZ) issued a forecasted increase, with an estimated annual net profit of 800 million to 860 million yuan, a year-on-year growth of 83% to 97%.

Jafron Biomedical (300529.SZ) disclosed its performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 8 billion to 8.6 billion yuan, a year-on-year increase of 83% to 97%; the net profit after deducting non-recurring gains and losses is expected to be 7.45 billion to 8.05 billion yuan, a year-on-year increase of 82% to 97%.